Memnon Lysandrou has graduated from the School of Medicine, University of Patras with a MD degree. During his undergraduate studies, he studied the mechanisms of immune evasion of relapsed Acute Leukaemia blasts following allogeneic Haemopoietic Cell Transplantion (allo-HCT).
He completed his PhD program at the Bone Marrow Transplantation Lab, School of Medicine, University of Patras working on the mechanistic analysis of Decitabine-treated HLA-G+CD4+ T cell-mediated immunosuppresion (funded by the Hellenic Foundation for Research & Innovation). He is also actively engaged in the design and implementation of the Phase I/II Study of inducible HLAG+ Regulatory T Cells (iG-Tregs) in patients undergoing HLA-matched sibling donor allo-HCT assessing the safety and efficacy of an HLA-G+CD4+ T cell-enriched cell product for the prophylaxis of GvHD (funded by the General Secretariat for Research & Innovation).
Finally, he is employing the CRISPR-Cas9 genome-editing platform to study the immunological aspects of Acute Myeloid Leukaemia (AML) to identify potentially key molecules triggering immune escape of relapsed blasts after allo-HCT.